Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ganymed Pharmaceuticals AG
ClinicalTrials.gov Identifier:
NCT00909025
First received: May 18, 2009
Last updated: March 11, 2014
Last verified: October 2012
  Purpose

Claudiximab is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. Preclinically, claudiximab was shown to inhibit tumor growth and to kill cancer cells by indirect (complement-dependent cytoxicity, antibody-dependent cellular cytotoxicity) and direct mechanisms (antiproliferative and proapoptotic effects). The aim of this phase I study is to establish safety, toxicity and maximal tolerable dose of a single infusion of claudiximab in patients suffering from relapsing, advanced gastroesophageal and gastric adenocarcinoma


Condition Intervention Phase
Solid Tumors
Drug: Claudiximab
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Clinical First-in-human Single-dose Escalation Study Evaluating the Safety and Tolerability of Claudiximab (iMAB-362) in Hospitalized Patients With Advanced Gastroesophageal Cancer. A Multi-center, Phase I, Open-label, i.v. Infusion Study

Resource links provided by NLM:


Further study details as provided by Ganymed Pharmaceuticals AG:

Primary Outcome Measures:
  • Determination of maximum tolerated dose of claudiximab (Phase I: toxicities as assessed by NCI CTCAE version 3.0) [ Time Frame: Four weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Determination of the safety profile [ Time Frame: Four weeks ] [ Designated as safety issue: Yes ]
  • Pharmacokinetic evaluation [ Time Frame: Four weeks ] [ Designated as safety issue: Yes ]
  • Overall tumor response as assessed by RECIST [ Time Frame: Four weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of immunogenicity [ Time Frame: Four weeks ] [ Designated as safety issue: Yes ]
  • Determination of antitumoral efficacy [ Time Frame: Four weeks ] [ Designated as safety issue: Yes ]

Enrollment: 15
Study Start Date: May 2009
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Claudiximab Drug: Claudiximab

Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT.

After completion of study treatment, patients are followed for 4 weeks.


  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Metastatic, refractory or recurrent disease of advanced gastroesophageal cancer (adenocarcinoma) proven by histology
  • CLDN18.2 expression confirmed by immunohistochemistry
  • Prior standard chemotherapy containing a fluoropyrimidine, a platinum compound and/or epirubicine, and - if clinically appropriate - docetaxel
  • At least 1 measurable site of the disease according RECIST criteria (CT-scans or MRT not older than 6 weeks before study entry)
  • Age ≥ 18 years
  • ECOG performance status (PS) 0-1 or Karnofsky Index 70-100%
  • Life expectancy > 3 months
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin ≥ 10 g/dl
  • INR < 1.5
  • Bilirubin normal
  • AST and ALT < 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
  • Creatinine < 1.5 x ULN

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Prior allergic reaction or intolerance to a monoclonal antibody
  • Prior inclusion in the present study
  • Less than 3 weeks since prior anti-tumor or radiation therapy
  • Other investigational agents or devices concurrently or within 4 weeks prior to this study
  • Other concurrent anticancer therapies
  • History of positive test for human immunodeficiency virus (HIV) antibody
  • Known Hepatitis.
  • Uncontrolled or severe illness.
  • Concurrent administration of anticoagulation agents with vitamin K antagonists
  • Concurrent administration of therapeutic doses of heparin (prophylactic doses are acceptable)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00909025

Locations
Germany
Universitätsklinikum Essen, Innere Klinik (Tumorforschung)
Essen, Germany, 45122
Universität Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT)
Heidelberg, Germany, 69120
Johannes Gutenberg Universität, 1.Med Klinik und Poliklinik
Mainz, Germany, 55131
Klinikum Rechts-der-Isar, III.Medizinische Klinik und Poliklinik
München, Germany, 81674
Latvia
Piejuras Hospital
Liepaja, Latvia, 3401
Pauls Stradins University
Riga, Latvia, 1002
Sponsors and Collaborators
Ganymed Pharmaceuticals AG
Investigators
Principal Investigator: Martin Schuler, Prof.Dr.med. Innere Klinik (Tumorforschung) Universitätsklinikum Essen Hufelandstr. 55 45122 Essen, GERMANY
  More Information

No publications provided

Responsible Party: Ganymed Pharmaceuticals AG
ClinicalTrials.gov Identifier: NCT00909025     History of Changes
Other Study ID Numbers: GM-IMAB-001
Study First Received: May 18, 2009
Last Updated: March 11, 2014
Health Authority: Germany: Paul-Ehrlich-Institut

ClinicalTrials.gov processed this record on November 25, 2014